Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTNM Contineum Therapeutics	$8.91 -4.2%	$5.08	$3.35 ▼ $20.55	$244.90M	1.04	134,195 shs	170,910 shs
GRCE Grace Therapeutics	$3.24 -1.5%	$3.09	$1.75 ▼ $4.97	$44.81M	0.72	60,441 shs	43,853 shs
KRRO Korro Bio	$19.12 -0.1%	$14.48	$10.29 ▼ $98.00	$179.64M	2.51	114,610 shs	35,638 shs
TIL Instil Bio	$25.13 -1.5%	$27.29	$10.80 ▼ $92.00	$169.59M	2.16	194,287 shs	119,165 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTNM Contineum Therapeutics	+14.81%	+37.78%	+113.79%	+140.93%	-49.97%
GRCE Grace Therapeutics	+1.86%	+2.81%	-2.08%	+12.67%	+328,999,900.00%
KRRO Korro Bio	-2.94%	+19.70%	+40.01%	+29.32%	-55.98%
TIL Instil Bio	-11.61%	-4.96%	-2.30%	+57.21%	+132.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTNM Contineum Therapeutics	3.447 of 5 stars	3.6	5.0	3.7	0.8	0.6
GRCE Grace Therapeutics	2.874 of 5 stars	3.5	0.0	3.5	0.8	1.3
KRRO Korro Bio	1.3182 of 5 stars	3.6	1.0	1.7	0.0	0.0
TIL Instil Bio	3.0426 of 5 stars	3.5	4.0	0.8	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTNM Contineum Therapeutics	3.17	Buy	$22.75	158.82% Upside
GRCE Grace Therapeutics	3.00	Buy	$12.00	270.37% Upside
KRRO Korro Bio	3.29	Buy	$86.83	349.68% Upside
TIL Instil Bio	3.00	Buy	$119.00	367.88% Upside

Current Analyst Ratings Breakdown

Latest GRCE, CTNM, KRRO, and TIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	CTNM Contineum Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$20.00 ➝ $21.00
8/15/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
8/13/2025	KRRO Korro Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
8/13/2025	KRRO Korro Bio	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Strong-Buy ➝ Strong-Buy	$153.00 ➝ $147.00
8/13/2025	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$100.00 ➝ $90.00
7/24/2025	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00
6/20/2025	CTNM Contineum Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/5/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
6/2/2025	TIL Instil Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/22/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$110.00 ➝ $105.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTNM Contineum Therapeutics	$50M	4.93	N/A	N/A	$6.11 per share	1.44
GRCE Grace Therapeutics	N/A	N/A	N/A	N/A	$4.60 per share	N/A
KRRO Korro Bio	$2.27M	79.88	N/A	N/A	$12.26 per share	1.58
TIL Instil Bio	N/A	N/A	N/A	N/A	$19.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTNM Contineum Therapeutics	-$42.26M	-$2.20	N/A	N/A	N/A	N/A	-29.75%	-28.08%	11/5/2025 (Estimated)
GRCE Grace Therapeutics	-$9.57M	-$0.86	N/A	N/A	N/A	N/A	-20.36%	-18.09%	N/A
KRRO Korro Bio	-$83.58M	-$9.75	N/A	N/A	N/A	N/A	-61.51%	-42.87%	N/A
TIL Instil Bio	-$74.14M	-$12.92	N/A	N/A	N/A	N/A	-54.32%	-33.65%	N/A

Latest GRCE, CTNM, KRRO, and TIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	TIL Instil Bio	-$1.72	-$3.24	-$1.52	-$3.24	N/A	N/A
8/12/2025	Q1 2026	GRCE Grace Therapeutics	-$0.22	-$0.21	+$0.01	-$0.21	N/A	N/A
8/12/2025	Q2 2025	KRRO Korro Bio	-$2.54	-$2.74	-$0.20	-$2.74	$0.41 million	$1.46 million
8/5/2025	Q2 2025	CTNM Contineum Therapeutics	-$0.56	-$0.62	-$0.06	-$0.62	$7.50 million	N/A
6/20/2025	Q4 2025	GRCE Grace Therapeutics	-$0.23	-$0.21	+$0.02	$0.01	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
GRCE Grace Therapeutics	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTNM Contineum Therapeutics	N/A	24.51	24.51
GRCE Grace Therapeutics	N/A	8.87	8.87
KRRO Korro Bio	N/A	5.98	5.98
TIL Instil Bio	0.64	14.97	14.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTNM Contineum Therapeutics	N/A
GRCE Grace Therapeutics	6.08%
KRRO Korro Bio	13.18%
TIL Instil Bio	60.56%

Insider Ownership

Company	Insider Ownership
CTNM Contineum Therapeutics	11.30%
GRCE Grace Therapeutics	11.10%
KRRO Korro Bio	4.60%
TIL Instil Bio	46.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTNM Contineum Therapeutics	31	28.04 million	24.87 million	N/A
GRCE Grace Therapeutics	N/A	13.83 million	12.29 million	N/A
KRRO Korro Bio	70	9.39 million	8.96 million	No Data
TIL Instil Bio	410	6.75 million	3.61 million	No Data

GRCE, CTNM, KRRO, and TIL Headlines

Recent News About These Companies

Instil Bio, Inc. (NASDAQ:TIL) is definitely on the radar of institutional investors who own 36% of the company

August 16, 2025 | finance.yahoo.com

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025 | finanznachrichten.de

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025 | globenewswire.com

Instil Bio Reports Promising Phase 2 Study Results

August 11, 2025 | theglobeandmail.com

Instil Bio stock rises after positive data for cancer therapy in China

July 31, 2025 | za.investing.com

Instil's licensed PD-L1xVEGF bispecific shows promise in China, instilling hope for upcoming US test

July 31, 2025 | fiercebiotech.comF

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

July 31, 2025 | globenewswire.com

US FDA clears Instil Bio’s IND application for AXN-2510, a PD-L1xVEGF bispecific antibody, for a phase 1 trial in relapsed/refractory solid tumours

July 4, 2025 | pharmabiz.comP

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed ...

July 3, 2025 | manilatimes.netM

Instil Bio Announces FDA Clearance for IND of AXN-2510, Phase 1 Trial Expected by End of 2025 - Nasdaq

July 3, 2025 | nasdaq.com

Instil Bio Shares Climb After FDA Clears Tumor Treatment Application

July 2, 2025 | marketwatch.com

Instil Bio stock jumps after FDA clearance of IND application

July 2, 2025 | in.investing.com

Instil Bio Shares Surge on FDA Clearance for Investigational Cancer Therapy

July 2, 2025 | msn.com

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

July 2, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/07/02/3109003/0/en/instil-bio-announces-u-s-f-d-a-clearance-of-investigational-new-drug-ind-application-for-axn-2510-a-pd-l1xvegf-bispecific-antibody-for-a-phase-1-trial-in-relapsed-refractory-solid-.html$

Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know

June 20, 2025 | zacks.com

Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet

June 16, 2025 | zacks.com

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

June 11, 2025 | globenewswire.com

Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice

June 4, 2025 | zacks.com

Instil Bio appoints new Chief Medical Officer

June 4, 2025 | uk.investing.com

Instil Bio appoints Jamie Freedman as Chief Medical Officer

June 2, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE, CTNM, KRRO, and TIL Company Descriptions

Contineum Therapeutics NASDAQ:CTNM

$8.91 -0.39 (-4.19%)

As of 02:41 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Grace Therapeutics NASDAQ:GRCE

$3.24 -0.05 (-1.52%)

As of 02:15 PM Eastern

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

Korro Bio NASDAQ:KRRO

$19.12 -0.02 (-0.13%)

As of 02:40 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Instil Bio NASDAQ:TIL

$25.12 -0.38 (-1.47%)

As of 02:41 PM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time